FDA clearance removes a key regulatory overhang for the AI Highlights feature in the U.S. market. Monitor upcoming quarterly results for initial U.S. adoption metrics and any update on CapsoCam Colon pipeline progress.
Price Chart
Executive Summary
CapsoVision announced FDA clearance of AI Highlights, its AI-assisted reading tool for the CapsoCam Plus capsule endoscopy system, on September 25, 2026. The tool is designed to reduce physician review time for small bowel capsule endoscopy studies performed due to suspected bleeding. This regulatory milestone opens the U.S. market for the AI feature, which had already launched internationally earlier in 2026.
Key Facts
- FDA clearance received September 25, 2026 for AI Highlights, an AI-assisted reading tool for the CapsoCam Plus system.
- AI Highlights is designed to reduce physician review time by recognizing and marking images with suspected abnormal lesions.
- The feature integrates with CapsoView software and CapsoCloud platform, supporting remote review and case management.
- AI Highlights had already launched internationally earlier in 2026, including in the European Union under the Medical Device Regulation.
- CapsoVision's next pipeline product is CapsoCam Colon with enhanced AI for non-invasive colon imaging and polyp detection.
Financial Impact
No financial figures provided in the filing. The FDA clearance opens the U.S. market for an AI feature already commercialized internationally, potentially expanding addressable revenue for the CapsoCam Plus system.
Risk Factors
- No revenue or financial data disclosed — unclear near-term revenue contribution from the AI feature.
- Competition in the capsule endoscopy market may limit adoption.
- Forward-looking statements about adoption and pipeline are aspirational and not guaranteed.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001378325-26-000045 |
| Document: cv-20260928xex991.htm | 0001378325-26-000045 |
| Document: 0001378325-26-000045-index-headers.html | 0001378325-26-000045 |
| Document: 0001378325-26-000045-index.html | 0001378325-26-000045 |
| Document: 0001378325-26-000045.txt | 0001378325-26-000045 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | 8-K | $6.92 | awaiting T+60 | — | $7.01 (+1.30%) |
Sep 28, 2026 28d ago | Press Release | $6.92 | awaiting T+60 | — | $7.01 (+1.30%) |
Sep 23, 2026 4w ago | Insider Cluster | $6.17 | awaiting T+60 | — | $7.01 (+13.61%) |
Sep 22, 2026 4w ago | Institutional Cluster | $6.30 | awaiting T+60 | — | $7.01 (+11.27%) |
Sep 18, 2026 5w ago | 424B5 | $6.70 | awaiting T+60 | — | $7.01 (−4.63%) |
Aug 24, 2026 9w ago | EFFECT | $5.83 | awaiting T+60 | — | $7.01 (−20.24%) |
Aug 13, 2026 10w ago | S-3 | $6.46 | awaiting T+60 | — | $7.01 (−8.51%) |
Jul 21, 2026 13w ago | Insider Buy | $6.91 $6.45 | ▼ −6.66% | ▼ −9.92% | $7.01 (+1.45%) |
Jul 10, 2026 15w ago | Insider Buy | $6.22 $6.50 | ▲ +4.50% | ▲ +0.51% | $7.01 (+12.70%) |
Jul 7, 2026 15w ago | Insider Buy | $6.13 $6.32 | ▲ +3.18% | ▲ +0.69% | $7.01 (+14.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers